RZRumin Zhang

Rumin Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rumin Zhang has a total of 328 co-authors. Here are the top co-authors by number of shared publications:

  • James Durkin

    7 shared publications
  • Nanhua Yao

    Schering–Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, USA

    6 shared publications
  • Richard Ingram

    Schering–Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, USA

    6 shared publications
  • Zhi Hong

    Schering–Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, USA

    6 shared publications
  • Lata Ramanathan

    Schering–Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, USA

    5 shared publications
  • William T. Windsor

    In Vitro Pharmacology, Merck Research Laboratories

    5 shared publications

Latest Publications

  • Open Access

    DCBK: A Fragment-Based Hybrid Simulation and Machine Learning Framework for Predicting Ligand Dissociation Kinetics

    by Yang Li, Yixin Wang, Xueying Zheng, Jinjiang Guo, Rumin Zhang

    Predicting small-molecule dissociation kinetics remains challenging due to the high computational cost of simulating rare unbinding events and the limited scalability of existing approaches. Here, we introduce DCBK (Divide-and-Compute Binding Kinetics), a physics-informed, fragment-resolved framework for predicting ligand dissociation across diverse protein–ligand systems. DCBK integrates steered molecular dynamics and umbrella sampling to reconstruct unbinding pathways and free energy profiles, followed by BRICS-based ligand fragmentation. Fragment-level energetic and structural features are combined with machine learning trained on experimental kinetics data, enabling efficient prediction of dissociation rate constant (k off ) values. Validation across five protein families demonstrates strong agreement with experiments, with ablation and unseen-target analyses highlighting the contribution of fragment-level features and the framework’s transferability. Importantly, DCBK allows dissociation kinetics to be interpreted in terms of fragment-level contributions, offering mechanistic insight and guiding ligand modification to optimize residence time. This interpretable and extensible framework links molecular structure, energetics, and kinetics, providing actionable insights for lead optimization and rational drug design.

  • Open Access

    GenVS-TBDB: A Target-Aware AI-Generated and Virtual-Screened Small-Molecule Library for Tuberculosis Drug Discovery

    by Xiaoying Lv, Han Guo, JingLan Wang, Qiping Hu, Mengyun Zhang, Heng Wang, Genhui Xiao, Xueying Zheng, Xi Lu, Zhuo Tang, et al.

    Tuberculosis (TB) remains a leading global health threat, with over 10 million new cases and 1.25 million deaths reported in 2023. Current TB therapies rely on a limited drug repertoire and prolonged treatment courses that have changed little in four decades. Here, we present GenVS-TBDB, a target-aware AI-generated and virtual-screened small-molecule database, which expands the chemical space against Mycobacterium tuberculosis (M.tb) essential proteins. We first identified 460 probable small-molecule binding pockets across 377 essential M.tb proteins by integrating multiple sources. Then, by leveraging the target-aware molecule generative model, over 1.2 million novel small molecules tailored to these pockets were produced. The key physicochemical properties were computed for all compounds to ensure medicinal chemistry tractability. These compounds were also evaluated using molecular docking and anti-TB specific graph neural network model, yielding binding propensity ranking and whole-cell activity prioritization for each target. To substantiate the integrated AI-driven workflow for anti-TB discovery, 30 compounds were obtained, including 22 AI-designed molecules synthesized de novo and 8 commercially available analogs. In validation, 2 synthesized compounds demonstrated significant thermal stabilization of FtsZ, confirming target engagement. 6 compounds exhibited cellular inhibition below 50 µM, the most potent at 12 µM. Furthermore, GDI-11785 showed binding to the cell wall biosynthesis pathway with 35 µM cellular activity, establishing a promising starting point for tuberculosis drug discovery. Our findings contribute a significant library of bioactive molecules which may hasten the preliminary phase of tuberculosis drug discovery. The GenVS-TBDB small library is publicly accessible and can be downloaded freely at https://datascience.ghddi.org/database/view .


  • Discovery of spiro amide SHR902275: A potent, selective, and efficacious RAF inhibitor targeting RAS mutant cancers

    by Peng Zhao, Linghang Zhuang, Xiangzhu Wang, Song Huang, Heping Wu, Yu Zhou, Yuna Yan, Fan Zhang, Ru Shen, Jing Li, et al.


  • Open Access

    Quantitative Measure of Receptor Agonist and Modulator Equi-Response and Equi-Occupancy Selectivity

    by Rumin Zhang, Michael Kavana

    G protein-coupled receptors (GPCRs) are an important class of drug targets. Quantitative analysis by global curve fitting of properly designed dose-dependent GPCR agonism and allosterism data permits the determination of all affinity and efficacy parameters based on a general operational model. We report here a quantitative and panoramic measure of receptor agonist and modulator equi-response and equi-occupancy selectivity calculated from these parameters. The selectivity values help to differentiate not only one agonist or modulator from another, but on-target from off-target receptor or functional pathway as well. Furthermore, in conjunction with target site free drug concentrations and endogenous agonist tones, the allosterism parameters and selectivity values may be used to predictin vivoefficacy and safety margins.


  • Moderate to high throughput in vitro binding kinetics for drug discovery

    by Rumin Zhang, Christopher M. Barbieri, Margarita Garcia-Calvo, Robert W. Myers, David McLaren, Michael Kavana

    This review provides a concise summary for state of the art, moderate to high throughput in vitro technologies being employed to studydrug-target binding kinetics. These technologies cover a wide kinetic timescale spanning up to nine orders of magnitude from milliseconds to days. Automated stopped flow measurestransient and (pre)steady state kinetics from milliseconds to seconds. For seconds to hours timescale kinetics we discuss surface plasmon resonance-based biosensor,global progress curve analysis for high throughput kinetic profiling of enzyme inhibitors and activators, and filtration plate-based radioligand or fluorescentbinding assays for receptor binding kinetics. Jump dilution after pre-incubation is the preferred method for very slow kinetics lasting for days. The basic principles,best practices and simulated data for these technologies are described. Finally, the application of a universal label-free technology, liquid chromatography coupledtandem mass spectrometry (LC/MS/MS), is briefly reviewed. Select literature references are highlighted for in-depth understanding. A new reality is dawning whereinbinding kinetics is an integral and routine part of mechanism of action elucidation and translational, quantitative pharmacology for drug discovery.


  • Selective small-molecule inhibition of an RNA structural element

    by John A. Howe, Hao Wang, Thierry O. Fischmann, Carl J. Balibar, Li Xiao, Andrew M. Galgoci, Juliana C. Malinverni, Todd Mayhood, Artjohn Villafania, Ali Nahvi, et al.

    Riboswitches are non-coding RNA structures located in messenger RNAs that bind endogenous ligands, such as a specific metabolite or ion, to regulate gene expression. As such, riboswitches serve as a novel, yet largely unexploited, class of emerging drug targets. Demonstrating this potential, however, has proven difficult and is restricted to structurally similar antimetabolites and semi-synthetic analogues of their cognate ligand, thus greatly restricting the chemical space and selectivity sought for such inhibitors. Here we report the discovery and characterization of ribocil, a highly selective chemical modulator of bacterial riboflavin riboswitches, which was identified in a phenotypic screen and acts as a structurally distinct synthetic mimic of the natural ligand, flavin mononucleotide, to repress riboswitch-mediated ribB gene expression and inhibit bacterial cell growth. Our findings indicate that non-coding RNA structural elements may be more broadly targeted by synthetic small molecules than previously expected.


  • Quantitative analysis of receptor allosterism and its implication for drug discovery

    by Rumin Zhang, Michael Kavana

    G protein-coupled receptors represent the largest class of druggable targets and are known to be modulated by both orthosteric agonists and positive/negative allosteric modulators (PAMs/NAMs). Proper experimental design and data analysis for the dose matrix between an agonist and PAM or NAM are critical to elucidate the key parameters for understanding molecular mechanism and structure-activity relationship (SAR) in drug discovery. The authors provide an overview and best practice recommendations on the quantitative analysis of receptor allosterism. The authors propose a simple classification system for receptor modulators on the basis of their efficacy and affinity modifiers. The authors also outline the optimal assay designs for both fixed dose screening and dose matrix study of receptor modulators. The authors recommend the global curve fitting approach to reliably yield system- and modulator-specific parameters for SAR ranking. Furthermore, the authors suggest that the uncertainty in maximal system response has insignificant impact on SAR ranking. The authors anticipate that systems pharmacology models integrating both binding kinetics and functional allosterism will be needed to address the inherent limitations of current allosterism models.


  • Iminopyrimidinones: A novel pharmacophore for the development of orally active renin inhibitors

    by Brian A. McKittrick, John P. Caldwell, Thomas Bara, George Boykow, Madhu Chintala, John Clader, Michael Czarniecki, Brandy Courneya, Ruth Duffy, Linda Fleming, et al.